(Total Views: 108)
Posted On: 11/22/2025 5:55:10 PM
Post# of 99739
BNCM https://www.otcmarkets.com/file/company/finan...16/content Note Last page of Filing:
POST MERGER PLANS & ACTIVITIES
1. DELEX Strategy Planning for 2025 and onwards in January 2025
2. Launch of Amsino (USA) product, Receptal, in February 2025.
3. Signing of Contract with Invokution (India) in Q1 2025.
4. Opening of 5 to 10 new Pharmacy Stores starting Q1 2025.
5. Announcement of Delex entitlement for Philips Imaging business in Q1 2025.
6. Signing of Partnership Contract with Yuwell (China) and launch of its Diabetes-related products,
including Continuous Glucose Monitors (CGM) and others in Q2 2025
7. Launch of Masimo (USA) products in Q3 2025.
8. Establish new Delex office in Makati, Philippines in Q3 2025
9. Installation of CT-Scan in St. Ireneaus which is scheduled for opening by Q4 2025 or Q1 2026.
10. MRI and Cathlab is expected to materialize in 2026 or early 2027.
11. Received approval of 4 Rad97 and Rad7 registrations. Indicative launch is on the 2nd quarter of 2026.
12. Strategic Partnership with LUYE Lifesciences to add CNS portfolio starting with Quetiapine (Seroquel), a market leader brand, is an antipsychotic originally developed by Astra Zeneca widely used for Schizophrenia, bipolar disorder and major depressive disorder.
13. Signing a Distribution Agreement with SOLM in Q3 2026.
14. Distribution Agreement with Amecath is being finalized a medical device company specializing in the development and manufacturing of catheters and related accessories.
15. Launch of Innovgas Products in Q3 2026
16. Signing of Partnership Agreement with Innokeys (Singapore) and launch of its comprehensive range of Oncology treatments in Q4 2025
17. Establishing a Strategic Partnership with Zuellig Pharma Corporation
18. Launch of NEW Products Q1 2026 under our own Brand Name.
OTC Markets Group Inc.
Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 7 of 7
POST MERGER PLANS & ACTIVITIES
1. DELEX Strategy Planning for 2025 and onwards in January 2025
2. Launch of Amsino (USA) product, Receptal, in February 2025.
3. Signing of Contract with Invokution (India) in Q1 2025.
4. Opening of 5 to 10 new Pharmacy Stores starting Q1 2025.
5. Announcement of Delex entitlement for Philips Imaging business in Q1 2025.
6. Signing of Partnership Contract with Yuwell (China) and launch of its Diabetes-related products,
including Continuous Glucose Monitors (CGM) and others in Q2 2025
7. Launch of Masimo (USA) products in Q3 2025.
8. Establish new Delex office in Makati, Philippines in Q3 2025
9. Installation of CT-Scan in St. Ireneaus which is scheduled for opening by Q4 2025 or Q1 2026.
10. MRI and Cathlab is expected to materialize in 2026 or early 2027.
11. Received approval of 4 Rad97 and Rad7 registrations. Indicative launch is on the 2nd quarter of 2026.
12. Strategic Partnership with LUYE Lifesciences to add CNS portfolio starting with Quetiapine (Seroquel), a market leader brand, is an antipsychotic originally developed by Astra Zeneca widely used for Schizophrenia, bipolar disorder and major depressive disorder.
13. Signing a Distribution Agreement with SOLM in Q3 2026.
14. Distribution Agreement with Amecath is being finalized a medical device company specializing in the development and manufacturing of catheters and related accessories.
15. Launch of Innovgas Products in Q3 2026
16. Signing of Partnership Agreement with Innokeys (Singapore) and launch of its comprehensive range of Oncology treatments in Q4 2025
17. Establishing a Strategic Partnership with Zuellig Pharma Corporation
18. Launch of NEW Products Q1 2026 under our own Brand Name.
OTC Markets Group Inc.
Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 7 of 7
(0)
(0)
